/UNCY
UNCY Stock - Unicycive Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$5.56+2.96%
+$0.16 (+2.96%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.62
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.47
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $6.12
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for UNCY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.50 – $5.62
TARGET (TP)$6.39
STOP LOSS$5.12
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.83
52W High$11.00
52W Low$3.71
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $675,000 | $951,000 | N/A | N/A |
| Gross Profit | N/A | $675,000 | $951,000 | N/A | N/A |
| Gross Margin | N/A | 100.0% | 100.0% | N/A | N/A |
| Operating Income | $-32,117,000 | $-20,774,000 | $-18,052,000 | $-8,977,000 | $-2,020,000 |
| Net Income | $-36,729,000 | $-30,544,000 | $-18,058,000 | $-10,017,000 | $-2,508,000 |
| Net Margin | N/A | -4525.0% | -1898.8% | N/A | N/A |
| EPS | $-5.60 | $-1.28 | $-1.20 | $-8.60 | $-0.16 |
Company Overview
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$8
Average Target
↑ 34.9% Upside
Now
$6
Low
$8
Average
$9
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 21st 2025 | Guggenheim | Initiation | Buy | $6 |
| April 4th 2024 | Piper Sandler | Initiation | Overweight | $9 |
Earnings History & Surprises
UNCYBeat Rate
41%
Last 17 quarters
Avg Surprise
-33.4%
EPS vs Estimate
Beats / Misses
7/9
1 met exactly
Latest EPS
$-0.39
Q4 2025
EPS Surprise History
Q4 23
0.0%
$-0.13vs$-0.13
Q1 24
+11.1%
$-0.16vs$-0.18
Q2 24
-50.0%
$-0.27vs$-0.18
Q3 24
+34.8%
$-0.15vs$-0.23
Q1 25
-23.1%
$-0.16vs$-0.13
Q1 25
-100.0%
$-0.26vs$-0.13
Q3 25
+25.7%
$-0.52vs$-0.70
Q4 25
+33.9%
$-0.39vs$-0.59
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.56 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.59 | $-0.39 | +33.9% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.70 | $-0.52 | +25.7% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.13 | $-0.26 | -100.0% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-0.13 | $-0.16 | -23.1% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.13 | — | — | — |
Q3 2024 | Aug 14, 2024 | $-0.23 | $-0.15 | +34.8% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.18 | $-0.27 | -50.0% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-0.18 | $-0.16 | +11.1% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.13 | $-0.13 | 0.0% | = MET |
Q3 2023 | Aug 14, 2023 | $-0.39 | $-0.29 | +25.6% | ✓ BEAT |
Q2 2023 | May 16, 2023 | $-0.36 | $-0.29 | +19.4% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $0.24 | $-0.35 | -245.8% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.35 | $-0.37 | -5.7% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.27 | $-0.24 | +11.1% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.20 | $-0.24 | -20.0% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-0.13 | $-0.17 | -30.8% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | $-0.11 | $-0.37 | -236.4% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-0.11 | $-0.13 | -18.2% | ✗ MISS |
Q1 2021 | Mar 31, 2021 | — | $-0.11 | — | — |
Latest News
Unicycive Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.
📈 PositiveBenzinga•Nov 12, 2025, 04:55 PM
Unicycive Therapeutics Q3 EPS $(0.46) Beats $(0.51) Estimate, Cash And Cash Equivalents Totaled $42.7M, With Cash Runway Into 2027
📈 PositiveBenzinga•Nov 12, 2025, 12:16 PM
HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Raises Price Target to $22
📈 PositiveBenzinga•Oct 29, 2025, 11:07 AM
Unicycive Therapeutics Plans To Resubmit NDA For Oxylanthanum Carbonate By Year-End
📈 PositiveBenzinga•Oct 28, 2025, 11:10 AM
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $21
📈 PositiveBenzinga•Sep 15, 2025, 12:57 PM
Unicycive Therapeutics Became Aware Of Securities Class Action Lawsuit
📉 NegativeBenzinga•Aug 18, 2025, 08:25 PM
Unicycive Therapeutics Receives US Patent For UNI-494 To Treat Chronic Kidney Disease, The Patent Follows The Issuance Of An Earlier Method Of Use Patent For Acute Kidney Injury With UNI-494
📈 PositiveBenzinga•Aug 18, 2025, 11:12 AM
Unicycive drops 25% following Complete Response Letter
📉 NegativeSeeking Alpha•Jun 30, 2025, 03:04 PM
Unicycive Therapeutics to execute 1-for-10 reverse stock split
📉 NegativeSeeking Alpha•Jun 17, 2025, 11:24 AM
Unicycive drops after FDA finds drug manufacturing issues
📉 NegativeSeeking Alpha•Jun 10, 2025, 01:43 PM
Frequently Asked Questions about UNCY
What is UNCY's current stock price?
Unicycive Therapeutics, Inc. (UNCY) is currently trading at $5.56 per share. The stock has moved +2.96% today.
What is the analyst price target for UNCY?
No analyst price targets are currently available for this stock.
What sector is Unicycive Therapeutics, Inc. in?
Unicycive Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is UNCY's market cap?
Unicycive Therapeutics, Inc. has a market capitalization of $0.10 billion, making it a small-cap company.
Does UNCY pay dividends?
No, Unicycive Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
BMEA
Biomea Fusion, Inc.
$1.40
Mkt Cap: $0.1B
CAMP
CAMP4 Therapeutics Corporation
$6.38
Mkt Cap: $0.1B
CBUS
Cibus, Inc.
$1.71
Mkt Cap: $0.1B
HYFT
MindWalk Holdings Corp.
$1.67
Mkt Cap: $0.1B
IMUX
Immunic, Inc.
$0.57
Mkt Cap: $0.1B
PMVP
PMV Pharmaceuticals, Inc.
$1.24
Mkt Cap: $0.1B
RLMD
Relmada Therapeutics, Inc.
$4.35
Mkt Cap: $0.3B
RPTX
Repare Therapeutics Inc.
$2.14
Mkt Cap: $0.1B
VXRT
Vaxart, Inc.
$0.35
Mkt Cap: $0.1B
Explore stocks similar to UNCY for comparison